Sold as Innovar. Every FDA application for this active ingredient: 1 branded and 4 generic. Boxed warning Withdrawn in Indonesia
As of Nov 22, 2026, FDA lists 5 applications for Droperidol; Fentanyl citrate (sold as Innovar), with 0 new uses approved and 0 published complete response letters.
| May 4, 1988 | Fentanyl Citrate and DroperidolANDA 71982 | Hospira | 5 | Discontinued |
| — | Fentanyl Citrate and DroperidolANDA 72026 | AstraZeneca Pharmaceuticals | 0 | Discontinued |
| — | Fentanyl Citrate and DroperidolANDA 72027 | AstraZeneca Pharmaceuticals | 0 | Discontinued |
| — | Fentanyl Citrate and DroperidolANDA 72028 | AstraZeneca Pharmaceuticals | 0 | Discontinued |
| — | InnovarNDA 16049 | Epic Pharma | 0 | Discontinued |
| Assessment of Drug Liking In Peri-procedural Clinical SettingsDrug Liking · Stanford University | Early phase 1 | Enrolling by invitation | Jun 11, 2025 |
| Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm RepairElective Surgical Procedures, Postoperative Pain · University of Crete | Phase 4 | Recruiting | May 20, 2021 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA